EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Ascletis Pharma's Enterprise Value is $1,219.22 Mil.
Ascletis Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-58.71 Mil. Therefore, Ascletis Pharma's EV-to-OCF for today is -20.77.
The historical rank and industry rank for Ascletis Pharma's EV-to-OCF or its related term are showing as below:
ASCLF'
s EV-to-OCF Range Over the Past 10 Years
Min: -49.35 Med: -1.94 Max: 9.09
Current: -20.86
During the past 10 years, the highest EV-to-OCF of Ascletis Pharma was 9.09. The lowest was -49.35. And the median was -1.94.
ASCLF's EV-to-OCF is ranked better than 81.22% of 1411
companies
in the Biotechnology industry
Industry Median: -3.51
vs ASCLF: -20.86
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ascletis Pharma's PE Ratio (TTM) for today is calculated as:
Ascletis Pharma's share price for today is $1.44.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ascletis Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.053.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ascletis Pharma EV-to-OCF Related Terms
Ascletis Pharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Ascletis Pharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ascletis Pharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascletis Pharma EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascletis Pharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Ascletis Pharma's EV-to-OCF falls into.
Ascletis Pharma's current Enterprise Value is $1,219.22 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ascletis Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-58.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascletis Pharma (ASCLF) has a EV-to-OCF of -20.77 as of Jul. 13, 2026. According to the industry distribution chart, Ascletis Pharma ranks #265 out of 1411 companies in the Biotechnology industry, placing it in the top 18.8%.
Is Ascletis Pharma's EV-to-OCF too high?
Ascletis Pharma's current EV-to-OCF is -20.77. Based on the distribution chart, Ascletis Pharma ranks #265 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ascletis Pharma has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ascletis Pharma's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascletis Pharma ranks #265 out of 1411 companies for EV-to-OCF. This places Ascletis Pharma in the top 19% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Ascletis Pharma's current EV-to-OCF is -20.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascletis Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ascletis Pharma (ASCLF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $1.44 — trading 7100% above its estimated fair value. The current EV-to-OCF is -20.77. Ascletis Pharma's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Ascletis Pharma (ASCLF), the current EV-to-OCF is -20.77 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascletis Pharma (ASCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued.
The current stock price of $1.44 is trading 7100% above its estimated GF Value™ of $0.02.
GuruFocus considers Ascletis Pharma to be Significantly Overvalued.
Key valuation signals for ASCLF:
EV-to-OCF: -20.77
GF Value™: $0.02 vs. price of $1.44 (7100% above fair value)
No single metric tells the full story. See the ASCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
38GF Score
Get the complete analysis for ASCLF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASCLF has been successfully added to your 
